Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Director · Executive Chairman | August 12, 2026 | August 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
X4 Pharmaceuticals, Inc
Report date August 12, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 328,651 |
Reported balance
After 2026-08-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-12 · Sale · Disposed 47,436 · Balance 328,651 F1: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.33 to $4.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Of the shares of common stock reported, 193,254 shares represent restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.33 to $4.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Of the shares of common stock reported, 193,254 shares represent restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CTI BIOPHARMA CORP
Report date June 26, 2023 · Filed June 26, 2023
Section 16 reporting ended · disclosed 2023-06-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 1
1 source rowRow 1 · 2023-06-26 · Other · Disposed 31,470 · Balance 0 F1: Includes 2,030 shares of common stock of the Issuer ("Company Common Stock") purchased by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan prior to the date of this Form 4. F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of Company Common Stock and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $9.10 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.24 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-26 · Disposition to issuer · Disposed 1,200,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.19 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-26 · Disposition to issuer · Disposed 450,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-06-26 · Disposition to issuer · Disposed 475,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.88 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-06-26 · Disposition to issuer · Disposed 600,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.84 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-06-26 · Disposition to issuer · Disposed 470,054 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-06-26 · Disposition to issuer · Disposed 2,320,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-06-26 · Disposition to issuer · Disposed 800,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.49 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-06-26 · Disposition to issuer · Disposed 1,115,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.55 | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-06-26 · Disposition to issuer · Disposed 900,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 2,030 shares of common stock of the Issuer ("Company Common Stock") purchased by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan prior to the date of this Form 4.
F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of Company Common Stock and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $9.10 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F3: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 09, 2022 Filed Nov 14, 2022 16:42 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 7,596 | $6.01 | $45,651.96 |
DisclosureSEC source: 0000891293-22-000056 · primary_doc.xml · nonDerivative · entry 3 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,161 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 16:42 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 46,100 | $6.00 | $276,600.00 |
DisclosureSEC source: 0000891293-22-000056 · primary_doc.xml · nonDerivative · entry 2 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,757 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 16:42 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 53,996 | $0.84 | $45,416.04 |
DisclosureSEC source: 0000891293-22-000056 · primary_doc.xml · nonDerivative · entry 1 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 16:35 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 242,300 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0000899243-22-031043 · doc4.xml · derivative · entry 3 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 913,254 Underlying: Common Stock · 242,300 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 16:35 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | SaleCommon Stock | 242,300 | $6.43 | $1,557,989.00 |
DisclosureSEC source: 0000899243-22-031043 · doc4.xml · nonDerivative · entry 2 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,861 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person. F2 · kind: The reporting person's sale of common stock reported herein may be deemed to be matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 5,000 shares of common stock purchased by the reporting person on August 16, 2022. The reporting person has sent to the Issuer the full amount of the disgorgeable profit arising from the sale reported herein. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.27 to $6.58, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 16:35 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionCommon Stock | 242,300 | $0.84 | $203,798.53 |
DisclosureSEC source: 0000899243-22-031043 · doc4.xml · nonDerivative · entry 1 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2022 Filed Aug 16, 2022 16:07 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Purchasecommon stock | 5,000 | $5.50 | $27,500.00 |
DisclosureSEC source: 0000891293-22-000044 · primary_doc.xml · nonDerivative · entry 1 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,861 Read SEC document |
| July 06, 2022 Filed Jul 6, 2022 17:19 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 18,223 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0000891293-22-000034 · primary_doc.xml · derivative · entry 10 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,155,554 Underlying: Common Stock · 18,223 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| July 06, 2022 Filed Jul 6, 2022 17:19 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 18,223 | $6.11 | $111,342.53 |
DisclosureSEC source: 0000891293-22-000034 · primary_doc.xml · nonDerivative · entry 7 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,861 F2 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| July 06, 2022 Filed Jul 6, 2022 17:19 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 18,223 | $0.84 | $15,327.37 |
DisclosureSEC source: 0000891293-22-000034 · primary_doc.xml · nonDerivative · entry 6 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 17:19 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0000891293-22-000034 · primary_doc.xml · derivative · entry 9 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,173,777 Underlying: Common Stock · 27,000 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 17:19 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 27,000 | $6.00 | $162,000.00 |
DisclosureSEC source: 0000891293-22-000034 · primary_doc.xml · nonDerivative · entry 5 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,861 F2 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 17:19 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 27,000 | $0.84 | $22,709.70 |
DisclosureSEC source: 0000891293-22-000034 · primary_doc.xml · nonDerivative · entry 4 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 17:19 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0000891293-22-000034 · primary_doc.xml · derivative · entry 8 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200,777 Underlying: Common Stock · 27,000 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 17:19 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 27,000 | $6.00 | $162,000.00 |
DisclosureSEC source: 0000891293-22-000034 · primary_doc.xml · nonDerivative · entry 3 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,861 F2 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 17:19 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 27,000 | $0.84 | $22,709.70 |
DisclosureSEC source: 0000891293-22-000034 · primary_doc.xml · nonDerivative · entry 2 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2022 Filed Jul 6, 2022 17:19 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Grantcommon stock | 6,183 | $2.12 | $13,086.32 |
DisclosureSEC source: 0000891293-22-000034 · primary_doc.xml · nonDerivative · entry 1 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,861 F1 · kind: Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan. Read SEC document |
| June 03, 2022 Filed Jun 3, 2022 19:15 UTC Amendment | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 18,223 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0000891293-22-000028 · primary_doc.xml · derivative · entry 3 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,227,777 Underlying: Common Stock · 18,223 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4/A amends the description of Title of Derivative Security previously reported on Form 4 filed on 6-3-2022. F2 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| June 03, 2022 Filed Jun 3, 2022 18:16 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock · Derivative | 18,223 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0000891293-22-000027 · primary_doc.xml · derivative · entry 9 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,227,777 Underlying: Common Stock · 18,223 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| June 03, 2022 Filed Jun 3, 2022 18:16 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 18,223 | $6.01 | $109,520.23 |
DisclosureSEC source: 0000891293-22-000027 · primary_doc.xml · nonDerivative · entry 6 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,678 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| June 03, 2022 Filed Jun 3, 2022 18:16 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 18,223 | $0.84 | $15,327.37 |
DisclosureSEC source: 0000891293-22-000027 · primary_doc.xml · nonDerivative · entry 5 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 19:15 UTC Amendment | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0000891293-22-000028 · primary_doc.xml · derivative · entry 2 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,246,000 Underlying: Common Stock · 27,000 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4/A amends the description of Title of Derivative Security previously reported on Form 4 filed on 6-3-2022. F2 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 18:16 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock · Derivative | 27,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0000891293-22-000027 · primary_doc.xml · derivative · entry 8 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,246,000 Underlying: Common Stock · 27,000 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 18:16 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 27,000 | $6.00 | $162,000.00 |
DisclosureSEC source: 0000891293-22-000027 · primary_doc.xml · nonDerivative · entry 4 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,678 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 18:16 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 27,000 | $0.84 | $22,709.70 |
DisclosureSEC source: 0000891293-22-000027 · primary_doc.xml · nonDerivative · entry 3 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 19:15 UTC Amendment | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0000891293-22-000028 · primary_doc.xml · derivative · entry 1 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,273,000 Underlying: Common Stock · 27,000 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4/A amends the description of Title of Derivative Security previously reported on Form 4 filed on 6-3-2022. F2 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 18:16 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock · Derivative | 27,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0000891293-22-000027 · primary_doc.xml · derivative · entry 7 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,273,000 Underlying: Common Stock · 27,000 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 18:16 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Salecommon stock | 27,000 | $6.00 | $162,000.00 |
DisclosureSEC source: 0000891293-22-000027 · primary_doc.xml · nonDerivative · entry 2 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,678 F1 · kind: This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 18:16 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Exercise / conversioncommon stock | 27,000 | $0.84 | $22,709.70 |
DisclosureSEC source: 0000891293-22-000027 · primary_doc.xml · nonDerivative · entry 1 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 19:39 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | GrantStock Option (right to buy) · Derivative | 1,115,000 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0000899243-22-010768 · doc4.xml · derivative · entry 2 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,115,000 Underlying: Common Stock · 1,115,000 shares Expires 2032-03-09 F2 · derivative.exercise_date: The stock option will vest in six equal semi-annual installments over a three-year period, subject to continued employment with the Company through the applicable vesting dates. Read SEC document |
| December 31, 2021 Filed Mar 11, 2022 19:39 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | GrantCommon Stock | 3,178 | $2.11 | $6,699.22 |
DisclosureSEC source: 0000899243-22-010768 · doc4.xml · nonDerivative · entry 1 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,678 F1 · kind: Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan. Read SEC document |
| December 02, 2021 Filed Dec 2, 2021 17:16 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Purchasecommon stock | 2,178 | $1.53 | $3,321.45 |
DisclosureSEC source: 0000891293-21-000045 · primary_doc.xml · nonDerivative · entry 3 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Read SEC document |
| December 02, 2021 Filed Dec 2, 2021 17:16 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Purchasecommon stock | 1,322 | $1.52 | $2,015.92 |
DisclosureSEC source: 0000891293-21-000045 · primary_doc.xml · nonDerivative · entry 2 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,322 Read SEC document |
| June 30, 2021 Filed Dec 2, 2021 17:16 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | Grantcommon stock | 5,000 | $2.13 | $10,625.00 |
DisclosureSEC source: 0000891293-21-000045 · primary_doc.xml · nonDerivative · entry 1 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 18:38 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | GrantStock Option (right to buy) · Derivative | 800,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0000899243-21-011360 · doc4.xml · derivative · entry 2 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires 2031-03-10 F2 · derivative.exercise_date: The stock option will vest in six equal semi-annual installments over a three-year period, subject to continued employment with the Company through the applicable vesting dates. The stock option is also subject to stockholder approval of an increase in the share reserve under the Company's 2017 Equity Incentive Plan, which approval must occur within one year from the grant date. Read SEC document |
| July 01, 2020 Filed Mar 12, 2021 18:38 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | GrantCommon Stock | 5,000 | $0.98 | $4,900.00 |
DisclosureSEC source: 0000899243-21-011360 · doc4.xml · nonDerivative · entry 1 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · kind: Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 19:30 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | GrantNon-qualified Stock Option · Derivative | 2,320,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0000891293-20-000014 · primary_doc.xml · derivative · entry 1 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,320,000 Underlying: Common stock · 2,320,000 shares Expires 2030-03-11 F1 · derivative.exercise_date: The stock option will vest in six equal semi-annual installments over a three-year period, subject to continued employment with the Company through the applicable vesting dates. The stock option is also subject to stockholder approval of an increase in the share reserve under the 2017 Equity Incentive Plan of the Company, which approval must occur within one year from the grant date. Read SEC document |
| May 16, 2019 Filed May 20, 2019 16:41 UTC | CTI BIOPHARMA CORP ctic · Entity 111865 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,300,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0000891293-19-000042 · primary_doc.xml · derivative · entry 1 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300,000 Underlying: Common Stock · 1,300,000 shares Expires 2029-05-16 F1 · derivative.exercise_date: One-third of the shares underlying the option will vest on February 19, 2020, and one-third of the shares underlying the option will vest annually thereafter, such that all of the shares subject to the option will be vested and exercisable on February 19, 2022, subject to Dr. Craig continuing to be an employee or a service provider through each such date. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 16:46 UTC | CTI BIOPHARMA CORP ctic · Entity 111865 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0000891293-18-000086 · primary_doc.xml · derivative · entry 1 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2028-09-18 F1 · derivative.exercise_date: The stock options will vest in six equal semi-annual installments over a three-year period commencing on September 18, 2018 subject to continued employment with the Company through the applicable vesting dates, such that the option will be fully vested on September 18, 2021. Read SEC document |
| May 16, 2018 Filed May 17, 2018 17:07 UTC | CTI BIOPHARMA CORP ctic · Entity 111865 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 475,000 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0000891293-18-000059 · primary_doc.xml · derivative · entry 1 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Stock · 475,000 shares Expires 2028-05-16 F1 · derivative.exercise_date: The stock option will vest in six equal semi-annual installments over a three-year period commencing on March 9, 2018 subject to continued employment with the Company through the applicable vesting dates, such that the option will be fully vested on March 9, 2021. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 17:16 UTC | CTI BIOPHARMA CORP ctic · Entity 111865 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 450,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0000891293-17-000108 · primary_doc.xml · derivative · entry 1 Craig Adam R · CIK 0001339498 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2027-09-29 F1 · derivative.exercise_date: The stock options vest in six equal installments over a three-year period beginning September 29, 2017 subject to continued employment by CTIC through the applicable vesting dates. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 19:09 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | GrantStock Option (Right to Buy) · Derivative | 1,200,000 | $0.00 Strike: $4.24 | $0.00 |
DisclosureSEC source: 0000899243-17-008320 · doc4.xml · derivative · entry 1 Craig Adam R · CIK 0001339498 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200,000 Underlying: Common Stock · 1,200,000 shares Expires 2027-03-19 F1 · derivative.exercise_date: The stock options will vest in six equal semi-annual installments over a three-year period beginning March 20, 2017, subject to Dr. Craig's continued employment by CTIC through the applicable vesting dates. The options will fully vest, to the extent then outstanding and unvested, if either (i) Dr. Craig's employment is terminated by CTIC without "Cause" or by him for "Good Reason" following a change in control of CTIC or (ii) Dr. Craig's employment is terminated due to his death or "Disability" (as such terms are defined in Dr. Craig's Employment Agreement). Of the total award, stock options covering 80,000 shares were granted under CTIC's 2015 Equity Incentive Plan and the balance were granted on a stand-alone basis (not under CTIC's 2015 Equity Incentive Plan) in accordance with NASDAQ Listing Rule 5635(c)(4). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.